Aspen Pharmacare’s turnaround now hinges on its sterile manufacturing, the costly network of injectable-drug plants it must fill. This follows last year’s collapse of a major mRNA contract. CEO Stephen Saad sums up the setback with a farmer’s phrase: “We lost the milk but not the cow.” The contract’s loss blew roughly R2bn out of…
Aspen Bets Recovery on Filling Sterile Manufacturing Lines
Original Article by Raymond Steyn | Financial Mail | 17 September 2026
Aspen Pharmacare's turnaround now hinges on its sterile manufacturing, the costly network of injectable-drug plants it must fill. This follows last year's collapse of a major mRNA contract. CEO Stephen Saad sums up the setback with a farmer's phrase: "We lost the milk but not the cow." The contract's loss blew roughly R2bn out of […]
Image | Rushay | Booysen | iStock/1335359769-1
More Posts
Sanlam Writes Down AfroCentric to Nil but Won’t Sell
Sanlam has written its AfroCentric stake down to nil after the Bonitas exit but rules out a sale, betting it can revive the business.
Read more...
GLP-1 Alone Won’t Solve South Africa’s Diabetes Crisis
GLP-1 medicines alone can’t solve SA’s diabetes crisis, experts warn, urging earlier screening, coordinated care and better food access.
Read more...
US Healthcare Affordability Crisis Squeezes Small Employers
The US healthcare affordability crisis is squeezing small employers the hardest, a mirror for local medical scheme debates.
Read more...